Compounds > farnesol

farnesol and Cancer of Pancreas

farnesol has been researched along with Cancer of Pancreas in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (25.00)18.2507
2000's3 (25.00)29.6817
2010's4 (33.33)24.3611
2020's2 (16.67)2.80

Authors

AuthorsStudies
Bacay, AF; Carrico-Moniz, D; Jun, M; Moyer, J; Webb, A1
Chen, M; Goodin, S; Li, D; Liu, W; Ma, Y; Ren, X; Sheng, Z; Xu, X; Zhang, K; Zheng, X; Zhou, R1
Azizian, NG; Du, R; Li, Y; Liu, Y; Sullivan, DK1
Bustinza-Linares, E; Kurzrock, R; Tsimberidou, AM1
Goldberg, L; Israeli, R; Kloog, Y1
Donehower, R; Goldsweig, H; Hidalgo, M; Jimeno, A; Laheru, D; Le, DT; Linden, S; McAllister, F; Rajeshkumar, NV; Rudek, MA; Shah, P; Song, D; Taylor, G; Zhao, M1
Egozi, Y; Elad-Sfadia, G; Haklai, R; Kloog, Y1
Burke, YD; Crowell, PL; Roach, SL; Sen, SE; Stark, MJ1
Fujii, T; Itoh, A; Kohgo, Y; Nishino, N; Obara, T; Shudo, R; Tanno, S; Ura, H1
Ben-Baruch, G; Egozi, Y; Gana-Weisz, M; Giehl, K; Gierschik, P; Kloog, Y; Marciano, D; Weisz, B1
Habiro, A; Izawa, T; Kohgo, Y; Mizukami, Y; Obara, T; Osanai, M; Tanno, S; Ura, H; Yanagawa, N1
Mizukami, Y1

Reviews

1 review(s) available for farnesol and Cancer of Pancreas

ArticleYear
Salirasib in the treatment of pancreatic cancer.
    Future oncology (London, England), 2010, Volume: 6, Issue:6

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Membrane; Clinical Trials, Phase I as Topic; Deoxycytidine; Disease-Free Survival; Drug Screening Assays, Antitumor; Farnesol; Farnesyltranstransferase; Galectins; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Middle Aged; Neoplasm Proteins; Neoplasms; Pancreatic Neoplasms; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Salicylates; Signal Transduction

2010

Trials

1 trial(s) available for farnesol and Cancer of Pancreas

ArticleYear
Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
    Investigational new drugs, 2012, Volume: 30, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Farnesol; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; Middle Aged; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); ras Proteins; Salicylates; Tumor Burden; Xenograft Model Antitumor Assays

2012

Other Studies

10 other study(ies) available for farnesol and Cancer of Pancreas

ArticleYear
Synthesis and biological evaluation of isoprenylated coumarins as potential anti-pancreatic cancer agents.
    Bioorganic & medicinal chemistry letters, 2014, Oct-01, Volume: 24, Issue:19

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Coumarins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Pancreatic Neoplasms; Structure-Activity Relationship

2014
Celecoxib combined with salirasib strongly inhibits pancreatic cancer cells in 2D and 3D cultures.
    International journal of medical sciences, 2020, Volume: 17, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Farnesol; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Salicylates; Signal Transduction

2020
Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells.
    BMC cancer, 2021, Mar-06, Volume: 21, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; CRISPR-Cas Systems; Drug Screening Assays, Antitumor; Endoplasmic Reticulum-Associated Degradation; Farnesol; Gene Knockout Techniques; Humans; Hydrazones; Hydroxyurea; Mice; Pancreatic Neoplasms; Proteins; Salicylates; Synthetic Lethal Mutations; Ubiquitin-Protein Ligases; Unfolded Protein Response

2021
FTS and 2-DG induce pancreatic cancer cell death and tumor shrinkage in mice.
    Cell death & disease, 2012, Mar-15, Volume: 3

    Topics: Animals; Antineoplastic Agents; Cell Death; Cell Proliferation; Deoxyglucose; Drug Synergism; Farnesol; Glycolysis; Humans; Mice; Mice, Nude; Organ Size; Pancreas; Pancreatic Neoplasms; Salicylates; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2012
Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:1

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Chromatography, Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Farnesol; Gemcitabine; Injections, Intraperitoneal; Mice; Mice, Nude; Pancreatic Neoplasms; Random Allocation; ras Proteins; Salicylates; Solvents; Survival Rate; Tandem Mass Spectrometry

2008
Inhibition of pancreatic cancer growth by the dietary isoprenoids farnesol and geraniol.
    Lipids, 1997, Volume: 32, Issue:2

    Topics: Acyclic Monoterpenes; Animals; Antineoplastic Agents; Carcinoma; Cricetinae; Drug Screening Assays, Antitumor; Farnesol; Humans; Mesocricetus; Monoterpenes; Pancreatic Neoplasms; Terpenes; Tumor Cells, Cultured

1997
Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts.
    Molecular carcinogenesis, 1998, Volume: 21, Issue:2

    Topics: 3T3 Cells; Alkyl and Aryl Transferases; Animals; Apoptosis; Cell Transformation, Neoplastic; DNA Fragmentation; Enzyme Inhibitors; Farnesol; Genes, ras; Mice; Pancreatic Neoplasms; Protein Prenylation; Proto-Oncogene Proteins p21(ras); Signal Transduction

1998
A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice.
    Oncogene, 1999, Apr-22, Volume: 18, Issue:16

    Topics: Animals; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinases; Dose-Response Relationship, Drug; Enzyme Activation; Epidermal Growth Factor; Farnesol; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; ras Proteins; Salicylates; Tumor Cells, Cultured

1999
Requirement of c-jun N-terminal kinase for apoptotic cell death induced by farnesyltransferase inhibitor, farnesylamine, in human pancreatic cancer cells.
    Biochemical and biophysical research communications, 2001, Oct-19, Volume: 288, Issue:1

    Topics: Alkyl and Aryl Transferases; Amines; Antineoplastic Agents; Apoptosis; Enzyme Inhibitors; Farnesol; Farnesyltranstransferase; Genes, ras; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinases; Mutation; Pancreatic Neoplasms; Tumor Cells, Cultured

2001
[Oleylamine (long-chain fatty amine)-induced cell death through MAP kinase pathways in human pancreatic cancer cells].
    [Hokkaido igaku zasshi] The Hokkaido journal of medical science, 2002, Volume: 77, Issue:1

    Topics: Amines; Apoptosis; Enzyme Inhibitors; Farnesol; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Tumor Cells, Cultured

2002